FibroGen Update on Pamrevlumab & Enrolling Non-Ambulatory Study (October 2017)
by: Parent Project Muscular Dystrophy
FibroGen Update on Pamrevlumab & Enrolling Non-Ambulatory Study (October 2017)
PPMD and FibroGen hosted a webinar on October 25, 2017 to hear a community update on FibroGen’s development of Pamrevlumab and currently enrolling FGCL-3019-079 non-ambulatory study in Duchenne.